ClinicaliQ Trial Snapshot
- A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Recruiting • Phase IV • Oncology • NCT07218341.
- Drug being tested: Pirtobrutinib (LY3527727), a second-generation Bruton's tyrosine kinase (BTK) inhibitor, is being evaluated for long-term safety and tolerability in patients with previously treated CLL/SLL who have completed an earlier phase trial.
- Patient eligibility overview: This is a continuation study for participants who successfully completed the prior pirtobrutinib trial (NCT 04666038), meaning patients have demonstrated prior response or tolerance to this agent and are seeking continued access to treatment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Eligibility Snapshot
- : * Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.